Literature DB >> 24412573

Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation.

Melissa D Howard1, Colin F Greineder2, Elizabeth D Hood1, Vladimir R Muzykantov3.   

Abstract

Production of excessive levels of reactive oxygen species (ROS) in the vascular endothelium is a common pathogenic pathway in many dangerous conditions, including acute lung injury, ischemia-reperfusion, and inflammation. Ineffective delivery of antioxidants to the endothelium limits their utility for management of these conditions. In this study, we devised a novel translational antioxidant intervention targeted to the vascular endothelium using PEG-liposomes loaded with EUK-134 (EUK), a potent superoxide dismutase/catalase mimetic. EUK loaded into antibody-coated liposomes (size 197.8±4.5 nm diameter, PDI 0.179±0.066) exerted partial activity in the intact carrier, while full activity was recovered upon liposome disruption. For targeting we used antibodies (Abs) to platelet-endothelial cell adhesion molecule (PECAM-1). Both streptavidin-biotin and SATA/SMCC conjugation chemistries provided binding of 125-150 Ab molecules per liposome. Ab/EUK/liposomes, but not IgG/EUK/liposomes: i) bound to endothelial cells and inhibited cytokine-induced inflammatory activation in vitro; and, ii) accumulated in lungs after intravascular injection, providing >60% protection against pulmonary edema in endotoxin-challenged mice (vs <6% protection afforded by IgG/liposome/EUK counterpart). Since the design elements of this drug delivery system are already in clinical use (PEG-liposomes, antibodies, SATA/SMCC conjugation), it is an attractive candidate for translational interventions using antioxidant molecules such as EUK and other clinically acceptable drugs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antioxidant enzyme mimetic; Antioxidant therapy; Endothelial targeting; Inflammation; Liposomes; Targeted drug delivery

Mesh:

Substances:

Year:  2014        PMID: 24412573      PMCID: PMC4593476          DOI: 10.1016/j.jconrel.2013.12.035

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  39 in total

1.  Functional mimics of superoxide dismutase enzymes as therapeutic agents.

Authors:  D P Riley
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

2.  PECAM-targeted delivery of SOD inhibits endothelial inflammatory response.

Authors:  Vladimir V Shuvaev; Jingyan Han; Kevin J Yu; Shaohui Huang; Brian J Hawkins; Muniswamy Madesh; Marian Nakada; Vladimir R Muzykantov
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

Review 3.  Targeting of superoxide dismutase and catalase to vascular endothelium.

Authors:  V R Muzykantov
Journal:  J Control Release       Date:  2001-03-12       Impact factor: 9.776

4.  Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme.

Authors:  V R Muzykantov; E N Atochina; A Kuo; E S Barnathan; K Notarfrancesco; H Shuman; C Dodia; A B Fisher
Journal:  Am J Physiol       Date:  1996-05

5.  EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology.

Authors:  Y Rong; S R Doctrow; G Tocco; M Baudry
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

6.  Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury.

Authors:  K Baker; C B Marcus; K Huffman; H Kruk; B Malfroy; S R Doctrow
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

7.  PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress.

Authors:  Melpo Christofidou-Solomidou; Arnaud Scherpereel; Rainer Wiewrodt; Kimmie Ng; Thomas Sweitzer; Evguenia Arguiri; Vladimir Shuvaev; Charalambos C Solomides; Steven M Albelda; Vladimir R Muzykantov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-08       Impact factor: 5.464

8.  Targeted detoxification of selected reactive oxygen species in the vascular endothelium.

Authors:  Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Faiz Bhora; Karine Laude; Hua Cai; Sergei Dikalov; Evguenia Arguiri; Charalambos C Solomides; Steven M Albelda; David G Harrison; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-08-19       Impact factor: 4.030

9.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

Authors:  C H Hennekens; J E Buring; J E Manson; M Stampfer; B Rosner; N R Cook; C Belanger; F LaMotte; J M Gaziano; P M Ridker; W Willett; R Peto
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

Review 10.  Redox signaling across cell membranes.

Authors:  Aron B Fisher
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

View more
  37 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.

Authors:  Makan Khoshnejad; Vladimir V Shuvaev; Katherine W Pulsipher; Chuanyun Dai; Elizabeth D Hood; Evguenia Arguiri; Melpo Christofidou-Solomidou; Ivan J Dmochowski; Colin F Greineder; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2016-01-15       Impact factor: 4.774

4.  Collaborative Enhancement of Endothelial Targeting of Nanocarriers by Modulating Platelet-Endothelial Cell Adhesion Molecule-1/CD31 Epitope Engagement.

Authors:  Ann-Marie Chacko; Jingyan Han; Colin F Greineder; Blaine J Zern; John L Mikitsh; Madhura Nayak; Divya Menon; Ian H Johnston; Mortimer Poncz; David M Eckmann; Peter F Davies; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2015-07-13       Impact factor: 15.881

5.  Activated protein C inhibits lung injury induced by LPS via downregulating MAPK signaling.

Authors:  Jianming Zhou; Ruoyu Hu; Shengjie Jing; Xin Xue; Wenhao Tang
Journal:  Exp Ther Med       Date:  2018-05-29       Impact factor: 2.447

Review 6.  Drug delivery systems, CNS protection, and the blood brain barrier.

Authors:  Ravi Kant Upadhyay
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

7.  Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.

Authors:  Krupa Savalia; Devika S Manickam; Erin G Rosenbaugh; Jun Tian; Iman M Ahmad; Alexander V Kabanov; Matthew C Zimmerman
Journal:  Free Radic Biol Med       Date:  2014-06-09       Impact factor: 7.376

8.  Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting.

Authors:  Colin F Greineder; Carlos H Villa; Landis R Walsh; Raisa Y Kiseleva; Elizabeth D Hood; Makan Khoshnejad; Robert Warden-Rothman; Andrew Tsourkas; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2017-12-29       Impact factor: 4.774

Review 9.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

Review 10.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.